EUCTR2021-000037-14-AT招募中1 期
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Aged =18 years and legal age of consent according to local regulations
- •2.Newly diagnosed and AL amyloidosis treatment naive with cardiac involvement
- •3.Confirmed diagnosis of AL amyloidosis
- •4.Confirmed Mayo Stage IV AL Amyloidosis as defined by NT-proBNP =1800 pg/mL and Troponin-T =0.025 ng/mL (mcg/L) or high sensitivity cardiac troponin T =40 ng/L and dFLC =18 mg/dL
- •5.Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly
- •A comprehensive list of inclusion criteria can be found in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •1.Non-AL amyloidosis
- •2.NT-proBNP >8500 pg/mL
- •3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma, except for malignancy biomarker of involved/and uninvolved serum free light chain ratio =100
- •4.Subject is eligible for and plans to undergo ASCT or organ transplant during the study
- •5.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit
- •6.Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area <1.0 cm2) or severe congenital heart disease
- •7.ECG evidence of acute ischemia or active conduction system abnormalities
- •8.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1
- •9.Prior radiotherapy within 4 weeks of Month 1-Day 1
- •10.Prior treatment with plasma cell-directed chemotherapy, birtamimab, daratumumab, 11-1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid
- •11.Waldenström's macroglobulinemia and/or immunoglobulin M monoclonal gammopathy
- •A comprehensive list of exclusion criteria can be found in the protocol.
研究者
相似试验
进行中（未招募）
1 期
A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) AmyloidosisAL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of abnormal AL protein (amyloid), in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac, renal, and hepatic dysfunction, gastrointestinal involvement and neuropathy and macroglossiaMedDRA version: 20.0Level: PTClassification code 10036673Term: Primary amyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2021-000037-14-DEProthena Biosciences Limited220
进行中（未招募）
1 期
A study to see how effective and safe NEO001 is when given together with the standard treatment in comparison to placebo together with the standard treatment in people with Light Chain (AL) Amyloidosis.ight chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble,fibrillar deposits of abnormal AL protein (amyloid),in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac,renal,and hepatic dysfunction,gastrointestinal involvement and neuropathy and macroglossiaMedDRA version: 18.0Level: PTClassification code 10036673Term: Primary amyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-003865-11-ESProthena Therapeutics Limited260
进行中（未招募）
1 期
A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) AmyloidosisEUCTR2021-000037-14-HUProthena Biosciences Limited150
进行中（未招募）
1 期
A study to see how effective and safe NEOD001 is when given together with the standard treatment in comparison to placebo together with the standard treatment in people with Light Chain (AL) Amyloidosis.ight chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble,fibrillar deposits of abnormal AL protein (amyloid),in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac,renal,and hepatic dysfunction,gastrointestinal involvement and neuropathy and macroglossiaMedDRA version: 20.0Level: PTClassification code 10036673Term: Primary amyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-003865-11-DKProthena Therapeutics Limited260
招募中
3 期
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) AmyloidosisMayo Stage IV Light Chain (AL) Amyloidosis10027476NL-OMON54039Prothena Biosciences Limited11